Biofrontera Inc. (BFRIW) Stock Price & Analysis
Biofrontera Inc. (BFRIW) rose 0.00% to USD 0.03 as of June 10, 2026 at 15:35 UTC, according to Nexqual real-time market data.
BFRIW last closed at USD 0.03; the session ranged USD 0.03–0.03 on volume of 0 shares. Market capitalization is —, with a 52-week range of USD 0.03–0.03 (NCM). Source: Nexqual, June 10, 2026 at 15:35 UTC.
Key Statistics (as of June 10, 2026 at 15:35 UTC)
| Price | USD 0.03 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0.03 |
| Open | USD 0.1 |
| Day Range | USD 0.03 – 0.03 |
| 52-Week Range | USD 0.03 – 0.03 |
| Volume | 0 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (BFRIW)
Nexqual's technical model rates BFRIW "BUY" based on 5 bullish and 2 bearish signals across 66 daily candles, as of June 10, 2026 at 15:35 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 100 (overbought) |
| vs SMA50 | Below (USD 0.06) |
| MACD | 0 (positive) |
Analyst Ratings (BFRIW)
Wall Street analysts rate BFRIW "None", per Nexqual as of June 10, 2026 at 15:35 UTC.
| Consensus Rating | None |
|---|
Earnings (BFRIW)
| Revenue Estimate | $9.50M |
|---|
Source: Nexqual, June 10, 2026 at 15:35 UTC.
Financials & Fundamentals (BFRIW)
| Total Revenue | $43.20M |
|---|---|
| Revenue Growth (YoY) | +17.40% |
| Gross Margin | +77.29% |
| Operating Margin | -38.95% |
| Profit Margin | -25.66% |
| ROE | -339.04% |
| Debt / Equity | 127.25 |
| Current Ratio | 1.21 |
| Total Cash | $6.33M |
| Total Debt | $7.72M |
| Free Cash Flow | $1.48M |
Source: Nexqual, June 10, 2026 at 15:35 UTC.
Financial Health Score (BFRIW)
Nexqual rates Biofrontera Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 15:35 UTC.
| Growth | Solid — Revenue +12% YoY (annual) |
|---|---|
| Profitability | Weak — Not yet profitable — scaling phase |
| Balance Sheet | Mixed — $6M cash vs $8M debt |
| Cash Flow | Mixed — FCF $1M, slim 3.5% margin |
| Efficiency | Critical — ROE -339%, ROA -32.4% |
Ownership (BFRIW)
| Float | 8.06M |
|---|
Source: Nexqual, June 10, 2026 at 15:35 UTC.
Leadership (BFRIW)
Biofrontera Inc. is led by Hermann Luebbert (age 69), CEO, President & Chairman, per Nexqual as of June 10, 2026 at 15:35 UTC.
| CEO, President & Chairman | Hermann Luebbert (age 69) |
|---|---|
| Chief Financial Officer | Eugene Frederick Leffler (age 40) |
| Vice President of Scientific & Medical Affairs | Jon Lyons |
| Senior Vice President of Sales & Strategic Accounts | Samantha Widdicombe |
Major Backers & Investors (BFRIW)
Notable institutional backers of Biofrontera Inc. include Bard Associates Inc., Susquehanna International Group, LLP, Clear Street Group Inc., according to Nexqual as of June 10, 2026 at 15:35 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Bard Associates Inc. | 10.38% |
| Susquehanna International Group, LLP | 3.07% |
| Clear Street Group Inc. | 0.61% |
Source: Nexqual, June 10, 2026 at 15:35 UTC.
From Biofrontera Inc.'s Latest SEC 10-K Filing (filed 2026-03-19)
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BFRI | Biofrontera Inc. | USD 0.87 | ▼ 6.67% |
| KTTAW | Pasithea Therapeutics Corp. Warrant | USD 0.01 | ▼ 37.61% |
| QTEXW | QTREX Quantum Ltd. | USD 0.16 | ▼ 28.18% |
| BBLGW | BONE BIOLOGICS CORP C/WTS (TO P | USD 14 | ▲ 0% |
| NRXPW | NRx Pharmaceuticals, Inc. | USD 0 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 15:35 UTC. This page is informational and not investment advice.